De-Risk & Accelerate Your Journey To The Clinic With Your Cell Therapy CDMO Partner
We support academic laboratories, biotechs, and pharma companies through development and GMP challenges. Hands-on expertise, clear communication, and a genuine commitment to your success. Less uncertainty. Faster timelines. A cell therapy CDMO partner you can rely on.
1000+
Clinical doses
manufactured in our GMP facility
15
Cell Types handled
T cells, NK cells, T regs, MSCs, iPS, immortalized cell lines…
50+
Development Programs
Process Development, Optimization, Scale up, Analytical & Potency test development
Translating an allogeneic adipose-derived MSC platform from an early clinical concept to GMP manufacturing
Turning a promising cell therapy concept into a clinical reality requires more than scientific innovation. It requires a development strategy capable of connecting research, process, manufacturing, quality and regulatory requirements from the outset.
The CellReady® program illustrates this journey through the development of an allogeneic MSC platform for the treatment of complex anal fistulas associated with Crohn’s disease. This case study looks at the development journey, the challenges encountered along the way, and the key decisions that shaped the path to clinical application.
Cell-Based Therapies Are Not Conventional Drugs. They’re Living Treatments.
Cell therapy programs don’t usually fail because of bad science, they fail because of execution gaps: processes that aren’t robust enough to scale, documentation that doesn’t hold up to regulatory scrutiny, and timelines that slip the moment complexity increases. As a cell therapy CDMO, closing these gaps is our core expertise. We bring the technical depth and manufacturing rigor needed to keep your program on track from early development through clinical success.
Broad Expertise Across Cell Therapy Modalities
Autologous and allogeneic, engineered (CAR/TCR) and non-engineered — including T-cells, NK cells, mesenchymal stem cells (MSCs), and iPSCs. Whatever your cell type, we’ve likely already solved a similar challenge.
Platform-Agnostic Cell Therapy Manufacturing
We operate independently of any specific platform or system, allowing us to adapt to your existing technologies and processes
Built for Regulatory Scrutiny
We ensure regulatory compliance at every stage, following ICH Q2 (R1), European Pharmacopeia, EMA/MHRA, and US Pharmacopeia standards, with a proven track record of successful audits.
CDMO Services To Accelerate Your Cell Therapy Development
Process Diagnostic
& Development
Analytical Development
GMP Cell Banking
GMP Manufacturing
Latest news
Stay on top of our latest breakthroughs.
Cell-Easy Expands Toulouse R&D Facility to Advance Three Next-Generation Cell Therapy Manufacturing Programs
Learn more: Cell-Easy Expands Toulouse R&D Facility to Advance Three Next-Generation Cell Therapy Manufacturing ProgramsToulouse, September 3, 2026 Cell-Easy, a specialized Contract Development and Manufacturing Organization (CDMO) dedicated to cell therapy, today announced the expansion of its R&D capabilities with the addition of >50 m² of new laboratory space at its Toulouse facility. The expansion strengthens Cell-Easy’s ability to conduct multiple development and scale-up programs in parallel, supporting customers…
ScaleReady Awards G-Rex® Grant to Support Cell-Easy as a European Hub for G-Rex®-Based Manufacturing
Learn more: ScaleReady Awards G-Rex® Grant to Support Cell-Easy as a European Hub for G-Rex®-Based ManufacturingToulouse, 2026 June 11th ScaleReady, a joint venture between Wilson Wolf and Bio-Techne and provider of scalable cell culture technologies, has awarded a G-Rex® Grant to Cell-Easy to support the development of a European hub for G-Rex®-based cell therapy manufacturing within the French CDMO. G-Rex® is widely recognized as a leading platform for scalable cell…
Cell-Easy Launches an iPSC-Derived Beta Cell Program to Tackle Scale-Up Challenges
Learn more: Cell-Easy Launches an iPSC-Derived Beta Cell Program to Tackle Scale-Up ChallengesCell-Easy Launches an iPSC-Derived Beta Cell Program to Tackle Scale-Up Challenges Backed by a €12M Bpifrance grant, the program builds a GMP-compatible manufacturing platform for iPSC-derived cell therapies directly applicable to biotech and pharma iPSC programs. Toulouse, 2026 April 14th Tackling one of the main bottlenecks in iPSC-derived therapies Scale-up remains one of the most…
They trusted us
Let’s talk about your project
Let’s turn your vision into a reality.
Phone: +33 534 276 550
Address: Cell-Easy SAS, 4 bis avenue Hubert Curien,
31100 Toulouse, France
Mail: info@cell-easy.com
